Eyenovia is a late-stage biopharmaceutical company with three lead programs in glaucoma, mydriasis and dry eye with a transformative ophthalmic delivery platform. Using breakthrough piezo-print technology for high-precision micro-dosing and the first smart electronic mobile health compliance tracking platform for topical pharmaceuticals, Eyenovia is building a premier eye care company of the future. The company is advancing its two lead assets for glaucoma and mydriasis into Phase III clinical programs and preparing registration studies for a third OTC product for dry eye. Eyenovia is expected to complete all three development programs through registration by 2020. Eyenovia is building a portfolio of superior micro-therapeutics with its proprietary piezo-formulations of existing and new molecular entities.
- 0.22 (4.01%)
Data provided by Nasdaq. Minimum 15 minutes delayed.
Eyenovia Reports Second Quarter 2018 Financial Results
Eyenovia’s EYN PG21 Trial Evaluating High-Precision Microdose of Latanoprost Demonstrates Robust Intraocular Pressure Lowering and Patient Usability
Eyenovia Announces Conference Call and Webcast for Second Quarter 2018 Financial Results
|There are currently no events scheduled.|
American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
(718) 921-8124 (phone)
(718) 921-8386 (fax)